Stifel raised the firm’s price target on GE HealthCare (GEHC) to $95 from $90 and keeps a Buy rating on the shares. The firm, which argues that the 2026 setup is constructive for large-cap MedTech following 2025 pressures, adjusted targets among its coverage and highlights Boston Scientific (BSX), Edwards Lifesciences (EW), and Solventum (SOLV) as its three top ideas entering the year.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare urges shareholders to reject ‘mini-tender’ offer by Potemkin
- Midday Fly By: Nvidia launches Rubin platform, Vistra to acquire Cogentrix
- NXP Semiconductors, GE HealthCare collaborate for AI in acute care
- GE HealthCare price target raised to $95 from $92 at Evercore ISI
- GE HealthCare price target raised to $92 from $82 at BofA